Neurones (France) Performance
| NRO Stock | EUR 48.95 0.60 1.21% |
On a scale of 0 to 100, Neurones holds a performance score of 9. The company secures a Beta (Market Risk) of 0.0506, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Neurones' returns are expected to increase less than the market. However, during the bear market, the loss of holding Neurones is expected to be smaller as well. Please check Neurones' kurtosis, market facilitation index, and the relationship between the semi variance and rate of daily change , to make a quick decision on whether Neurones' current price movements will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Neurones are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Neurones may actually be approaching a critical reversion point that can send shares even higher in April 2025. ...more
| Begin Period Cash Flow | 266.5 M | |
| Total Cashflows From Investing Activities | -10.6 M |
Neurones |
Neurones Relative Risk vs. Return Landscape
If you would invest 4,380 in Neurones on December 19, 2024 and sell it today you would earn a total of 515.00 from holding Neurones or generate 11.76% return on investment over 90 days. Neurones is generating 0.1954% of daily returns assuming 1.6164% volatility of returns over the 90 days investment horizon. Simply put, 14% of all stocks have less volatile historical return distribution than Neurones, and 97% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Neurones Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neurones' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Neurones, and traders can use it to determine the average amount a Neurones' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1209
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | NRO | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.62 actual daily | 14 86% of assets are more volatile |
Expected Return
| 0.2 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.12 actual daily | 9 91% of assets perform better |
Based on monthly moving average Neurones is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Neurones by adding it to a well-diversified portfolio.
Neurones Fundamentals Growth
Neurones Stock prices reflect investors' perceptions of the future prospects and financial health of Neurones, and Neurones fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Neurones Stock performance.
| Return On Equity | 0.14 | |||
| Return On Asset | 0.077 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.11 % | |||
| Current Valuation | 735.59 M | |||
| Shares Outstanding | 24.22 M | |||
| Price To Earning | 21.03 X | |||
| Price To Book | 3.01 X | |||
| Price To Sales | 1.50 X | |||
| Revenue | 579.88 M | |||
| EBITDA | 72.17 M | |||
| Cash And Equivalents | 169.6 M | |||
| Cash Per Share | 7.20 X | |||
| Total Debt | 27.82 M | |||
| Debt To Equity | 0.10 % | |||
| Book Value Per Share | 12.78 X | |||
| Cash Flow From Operations | 64.5 M | |||
| Earnings Per Share | 1.71 X | |||
| Total Asset | 567.82 M | |||
| Retained Earnings | 21 M | |||
| Current Asset | 284 M | |||
| Current Liabilities | 133 M | |||
About Neurones Performance
By analyzing Neurones' fundamental ratios, stakeholders can gain valuable insights into Neurones' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Neurones has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Neurones has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Neurones S.A., an information technology services company, provides infrastructure, application, and consulting services in France and internationally. Neurones S.A. was founded in 1985 and is headquartered in Nanterre, France. NEURONES operates under Information Technology Services classification in France and is traded on Paris Stock Exchange. It employs 5160 people.Things to note about Neurones performance evaluation
Checking the ongoing alerts about Neurones for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Neurones help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| About 71.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Neurones' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Neurones' stock is overvalued or undervalued compared to its peers.
- Examining Neurones' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Neurones' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Neurones' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Neurones' stock. These opinions can provide insight into Neurones' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Neurones Stock analysis
When running Neurones' price analysis, check to measure Neurones' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurones is operating at the current time. Most of Neurones' value examination focuses on studying past and present price action to predict the probability of Neurones' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurones' price. Additionally, you may evaluate how the addition of Neurones to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |